NASDAQ$SPRB
Spruce Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings ·
Briefing
SPRB Q3 2024 — $600K revenue
We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. Spruce Biosciences Inc reported Q3 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $600K.
- Operating income: $9K.
- Filed on Form 10-Q (accession 0000950170-24-124479).
Headline financials
Revenue & EPS history
Spruce Biosciences Inc · Revenue · Quarterly
$602K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2024
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-0.6%
Avg return
30 days after
27%
4 / 15 earnings
Positive
+6.1%
Q3 2022
Best reaction
-10.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.1% | -9.3% | -9.5% | |
| Q3 2025 | -2.6% | -8.0% | -23.5% | |
| Q2 2025 | -5.9% | -4.2% | +33.3% | |
| Q1 2025 | -1.4% | +4.2% | -9.7% | |
| Q3 2024 | -1.3% | -7.9% | -27.4% | |
| Q2 2024 | -4.6% | +3.2% | +7.3% | |
| Q1 2024 | -3.4% | -10.0% | -20.2% | |
| Q3 2023 | +2.9% | +28.6% | +65.7% | |
| Q2 2023 | -1.6% | +5.6% | +11.9% | |
| Q1 2023 | -2.2% | +4.5% | +6.3% | |
| Q3 2022 | +6.1% | +6.1% | +3.0% | |
| Q2 2022 | +1.0% | +10.8% | -7.2% | |
| Q1 2022 | -10.5% | -6.3% | +8.4% | |
| Q3 2021 | -1.9% | -34.5% | -44.1% | |
| Q2 2021 | -2.2% | -5.2% | -3.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro